Skip to main content

Table 1 Extension Phase Baseline Patient Characteristics

From: Atomoxetine for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children with ADHD and dyslexia

Characteristic

ADHD (N = 20)

ADHD+D (N = 36)

Gender, male, n (%)

15 (75.0)

24 (66.7)

Age, years, mean (SD)

12.7 (1.5)

12.2 (2.0)

Ethnic origin, n (%)

  

   Caucasian

14 (70.0)

24 (66.7)

   African-American

1 (5.0)

5 (13.9)

   Hispanic

4 (20.0)

4 (11.1)

   Other

1 (5.0)

3 (8.3)

ADHD subtype, n (%)

  

   Hyperactive/Impulsive

0 (0)

2 (5.6)

   Inattentive

9 (45.0)

15 (41.7)

   Combined

11 (55.0)

19 (52.8)

Educational services - placement, n (%)a

  

   Regular education

7 (35.0)

3 (8.3)

   Regular education/Resource room

7 (35.0)

11 (30.6)

   Regular education/Special education

4 (20.0)

14 (38.9)

   Self-contained special education/Integration

1 (5.0)

5 (13.9)

   Self-contained special education/No integration

0 (0)

3 (8.3)

   Private school - disabilities

1 (5.0)

0 (0)

K-BIT, mean (SD) IQ composite

97.2 (11.9)

102.1 (11.0)

  1. a p-value ≤ .05 for between-group difference.
  2. Abbreviations: ADHD = attention-deficit/hyperactivity disorder group; ADHD+D = ADHD and dyslexia group; K-BIT = Kaufman Brief Intelligence Test; n = sample size; SD = standard deviation.